Vatalinib Uses, Dosage, Side Effects and more
Vatalinib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalinib is under investigation for the treatment of solid tumors.
Vatalinib is a novel oral angiogenesis inhibitor being developed by Schering (in collaboration with Novartis AG). Vatalinib selectively inhibits the tyrosine kinase domains of vascular endothelial growth factor (VEGF) receptors, platelet-derived growth factor (PDGF) receptor, and c-KIT.
| Trade Name | Vatalinib |
| Generic | Vatalanib |
| Vatalanib Other Names | Vatalanib, Vatalinib |
| Type | |
| Formula | C20H15ClN4 |
| Weight | Average: 346.813 Monoisotopic: 346.098524207 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Used in combination with first- and second-line chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC).
How Vatalinib works
Vatalinib potently inhibits vascular endothelial growth factor (VEGF) receptor tyrosine kinases, important enzymes in the formation of new blood vessels that contribute to tumor growth and metastasis.
Elimination Route
Rapid onset of absorption
Half Life
Approximately 6 hours.
